 BRISBANE, Calif., May 05, 2022 GLOBE NEWSWIRE -- Annexon, Inc. Nasdaq: ANNX, a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that Douglas Love, Esq., president chief executive officer, will participate in fireside chats during the following May investor conferences: 